Sign In
Buy GTHX
$7.15
+0 (+0%)
At Close: Dec 16, 2024
Why Is G1 Therapeutics (GTHX) Stock Down 56% Today?
08:23am, Monday, 24'th Jun 2024
G1 Therapeutics (NASDAQ: GTHX ) stock is falling hard on Monday after the company provided investors with an update on its Phase 3 clinical trial of trilaciclib as a breast cancer treatment. G1 Thera
G1 Therapeutics' breast cancer drug fails in late-stage trial
07:14am, Monday, 24'th Jun 2024
G1 Therapeutics said on Monday its drug for a rare, aggressive form of breast cancer did not meet the main goal of overall survival in a late-stage trial.
G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negativ
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Wednesday, 05'th Jun 2024
RESEARCH TRIANGLE PARK, N.C., June 05, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced the grant of inducement stock options exerci
- New Positive Phase 2 Results in Metastatic Triple Negative Breast Cancer (mTNBC) Indicate That Use of Trilaciclib in Combination with a TROP2 ADC May Be Associated with Improved Median OS Compared t
G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting
05:06pm, Thursday, 23'rd May 2024
RESEARCH TRIANGLE PARK, N.C., May 23, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that mature Phase 2 results describing the pos
G1 Therapeutics to Participate in TD Cowen's 5th Annual Oncology Innovation Summit
10:00am, Wednesday, 22'nd May 2024
RESEARCH TRIANGLE PARK, N.C., May 22, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1's Chief Medical Officer Dr. Raj Malik
G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective Uses
06:30am, Wednesday, 22'nd May 2024
RESEARCH TRIANGLE PARK, N.C. and SAN FRANCISCO, May 22, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, and Deimos Biosciences, a portfolio company
2 Biotech Stocks to Watch Under $20
02:37pm, Thursday, 09'th May 2024
Biotech stocks are a tricky bunch, prone to wild moves and technical patterns that are tough to nail down.
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:50pm, Wednesday, 01'st May 2024
RESEARCH TRIANGLE PARK, N.C., May 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisa
G1 Therapeutics, Inc. (GTHX) Q1 2024 Earnings Call Transcript
12:04pm, Wednesday, 01'st May 2024
G1 Therapeutics, Inc. (NASDAQ:GTHX ) Q1 2024 Earnings Conference Call May 1, 2024 8:30 AM ET Company Participants Will Roberts - Investor Relations Jack Bailey - Chief Executive Officer Andrew Perry -
G1 Therapeutics (GTHX) Reports Q1 Loss, Lags Revenue Estimates
08:41am, Wednesday, 01'st May 2024
G1 Therapeutics (GTHX) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.53 per share a year ago.
G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights
06:30am, Wednesday, 01'st May 2024
- Achieved $14.1 Million in Net Revenue from Sales of COSELA® (trilaciclib) for First Quarter 2024 - - Reaffirmed 2024 Net COSELA Revenue Guidance of $60 to $70 Million - - Announced That Updated Eff
G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib
06:25am, Wednesday, 01'st May 2024
RESEARCH TRIANGLE PARK, N.C. and BOSTON, May 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, and Pepper Bio, the world's first transomics drug d
G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024
09:00am, Wednesday, 17'th Apr 2024
RESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, will host a webcast and conference call to provide a financ
